NCT07229534尚未招募4 期
A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 238
- 主要终点
- Change from baseline of HbA1c(%)
研究概览
简要总结
This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •7.0%≤HbA1c≤10.5% and fasting glucose≤270mg/dL
- •Treated with 1,000mg/day dose of metformin for at least 8 weeks
排除标准
- •Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
- •eGFR<45mL/min/1.73m2
- •ALT and AST 3 times or higher than upper normal range
- •Determined by investigator as unfit to participate in a clinical trial due to other reasons
研究组 & 干预措施
DA-5218
Experimental
干预措施: DA-5218 (Drug)
DA-5218-C
Active Comparator
干预措施: DA-5218-C (Drug)
结局指标
主要结局
Change from baseline of HbA1c(%)
时间窗: 24 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the KneeOsteoarthritis of KneeNCT02682524Daewon Pharmaceutical Co., Ltd.191
已完成
4 期
Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71Hand, Foot and Mouth DiseaseNCT03582761Jiangsu Province Centers for Disease Control and Prevention40,000
已完成
4 期
Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive KeratectomyPhotorefractive KeratectomyCorneal De-epithelializationNCT04704518Laboratorios Sophia S.A de C.V.96
终止
4 期
Safety and Efficacy of Cefecin Tab. in Patients With Acute SinusitisAcute SinusitisNCT04664803Korea United Pharm. Inc.284
已完成
4 期
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With MonotherapyHypertensionNCT02433119Dong-A ST Co., Ltd.238
